Home › Compare › SEIBF vs ABBV
SEIBF yields 0.82% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, SEIBF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SEIBF + ABBV for your $10,000?
Seibu Holdings Inc. engages in the urban and regional transportation, hotel and leisure, real estate, construction, and baseball team management businesses in Japan and internationally. It operates through Urban Transportation and Regional, Hotel and Leisure, Real Estate, and Other Business segments. The company offers railway, bus, and taxi transportation services; operates hotels, hot springs and spas, golf courses, ski resorts, tennis courts, bowling alleys, skating rinks, fitness clubs, and other leisure facilities; develops and sells housing, condominiums, and resort properties; leases office and residential facilities; and develops and operates stores in train stations, shopping malls, and other commercial facilities. It also maintains a professional baseball team under Saitama Seibu Lions name; hosts concerts and other non-baseball events through Belluna Dome; and operates and manages amusement parks, aquariums, movie theaters, and pools. In addition, the company offers fire insurance, automobile insurance, travel insurance, and life insurance products. Further, it provides travel agency; housekeeping; child-rearing support; home and urban development services; and pet care products, as well as builds cemeteries. Seibu Holdings Inc. was incorporated in 2006 and is headquartered in Tokyo, Japan.
Full SEIBF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.